CTMX
CytomX Therapeutics, Inc.
$3.01
+1.01%
$655.3M
No data for this timeframe.
Vol
Market Cap$655.3M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders50 funds
Inst. Value$510.9M
Inst. Activity16 buys / 5 sells
Insider Activity0B / 4S
Insider Net $-$1.2M
Reddit Sentiment67° Warm
Press Releases4
Recent Activity
Mar 17, 2026
Insider
Ogden Christopher sold 19,323 shares
Chief Financial Officer @ $6.42 ($124.1K)
Mar 17, 2026
Insider
BELVIN MARCIA sold 31,492 shares
SVP, Chief Scientific Officer @ $6.42 ($202.3K)
Mar 17, 2026
Insider
McCarthy Sean A. sold 118,969 shares
CEO @ $6.42 ($764.1K)
Inst.
FMR LLC — ADD
31,955,637 shares ($150.2M)
Inst.
BANK OF AMERICA CORP — DOUBLED
10,202,785 shares ($48.0M)
Jun 3, 2026
contract
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
<p align="center"><em>- Expanded collaboration builds upon research momentum in developing next-gene
Mar 18, 2026
Press
CytomX Therapeutics priced a public offering of 45,990,567 shares and pre-funded warrants for 1,179,245 shares at $5.30
Impact 6/10
Mar 16, 2026
Press
CytomX Therapeutics announced a public offering of $250.0 million in common stock and pre-funded warrants, with an addit
Impact 7/10
Price Targets
$12.50
+315.3% upside
Strong Buy
Current $3.01
Low $6.00
Median $12.00
High $16.00
8 analysts
$6.00
$16.00
Analyst Ratings
7Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 23, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Mar 19, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Mar 18, 2026 | Jefferies | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.10 ▲ +1.2% | $-0.13 — $-0.07 | 0% YoY | 6 |
| Next Q | $-0.11 ▲ +4.5% | $-0.14 — $-0.07 | -17% YoY | 6 |
| Current FY | $-0.42 ▲ +2.9% | $-0.51 — $-0.34 | -181% YoY | 6 |
| Next FY | $-0.49 ▲ +2.1% | $-0.81 — $-0.25 | -15% YoY | 7 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $150.2M | ADD |
| BANK OF AMERICA CORP | $48.0M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $41.0M | — |
| Point72 Asset Management, L.P. | $37.0M | ADD |
| STATE STREET CORP | $26.6M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 17, 2026 | Ogden Christopher | SELL | $124.1K |
| Mar 17, 2026 | BELVIN MARCIA | SELL | $202.3K |
| Mar 17, 2026 | McCarthy Sean | SELL | $764.1K |
| Mar 17, 2026 | Chu Yu-Waye | SELL | $136.7K |
| Feb 2, 2026 | Chu Yu-Waye | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $510.9M total value (108,708,510 shares) as of 2026-Q1. Top holders: FMR, BANK, VANGUARD. Net buying activity: 16 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 31,955,637 | $150.2M | 29.4% | ADD +29.4% |
| 2 | BANK OF AMERICA CORP /DE/ | 10,202,785 | $48.0M | 9.4% | DOUBLED +676.2% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 8,733,118 | $41.0M | 8.0% | — |
| 4 | Point72 Asset Management, L.P. | 7,875,390 | $37.0M | 7.2% | ADD +51.8% |
| 5 | STATE STREET CORP | 5,663,408 | $26.6M | 5.2% | DOUBLED +697.1% |
| 6 | CITADEL ADVISORS LLC | 5,406,193 | $25.4M | 5.0% | DOUBLED +2005.6% |
| 7 | BlackRock, Inc. | 5,228,280 | $24.6M | 4.8% | ADD +42.5% |
| 8 | BAKER BROS. ADVISORS LP | 4,975,826 | $23.4M | 4.6% | — |
| 9 | MARSHALL WACE, LLP | 4,138,176 | $19.4M | 3.8% | DOUBLED +257.7% |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 3,582,985 | $16.8M | 3.3% | NEW |
| 11 | TWO SIGMA INVESTMENTS, LP | 2,710,156 | $12.7M | 2.5% | DOUBLED +113.9% |
| 12 | Woodline Partners LP | 2,000,825 | $9.4M | 1.8% | — |
| 13 | DIMENSIONAL FUND ADVISORS LP | 1,930,920 | $9.1M | 1.8% | ADD +49.7% |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,869,615 | $8.8M | 1.7% | — |
| 15 | GOLDMAN SACHS GROUP INC | 1,459,839 | $6.9M | 1.3% | — |
| 16 | VANGUARD FIDUCIARY TRUST CO | 1,102,883 | $5.2M | 1.0% | — |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 907,800 | $4.3M | 0.8% | — |
| 18 | Trexquant Investment LP | 898,767 | $4.2M | 0.8% | — |
| 19 | VANGUARD PORTFOLIO MANAGEMENT LLC | 794,755 | $3.7M | 0.7% | — |
| 20 | BALYASNY ASSET MANAGEMENT L.P. | 730,844 | $3.4M | 0.7% | NEAR_EXIT -81.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 24,688,109 | 31,955,637 | +29.4% | $150.2M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 876,305 | 10,202,785 | +676.2% | $48.0M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 5,189,538 | 7,875,390 | +51.8% | $37.0M | 2026-Q1 |
| BlackRock, Inc. | ADD | 3,669,393 | 5,228,280 | +42.5% | $24.6M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 1,156,936 | 4,138,176 | +257.7% | $19.4M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | NEW | — | 3,582,985 | — | $16.8M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 1,289,656 | 1,930,920 | +49.7% | $9.1M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEAR_EXIT | 3,872,202 | 730,844 | -81.1% | $3.4M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 423,168 | 568,562 | +34.4% | $2.7M | 2026-Q1 |
| MORGAN STANLEY | ADD | 401,191 | 520,495 | +29.7% | $2.4M | 2026-Q1 |
| Assenagon Asset Management S.A. | TRIM | 592,696 | 364,173 | -38.6% | $1.7M | 2026-Q1 |
| Brevan Howard Capital Management LP | DOUBLED | 11,404 | 269,202 | +2260.6% | $1.3M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 124,124 | 248,248 | +100.0% | $1.2M | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 68,687 | 128,796 | +87.5% | $605.3K | 2026-Q1 |
| Jain Global LLC | DOUBLED | 21,212 | 104,750 | +393.8% | $492.3K | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 50,990 | 80,663 | +58.2% | $379.1K | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 229,599 | 65,015 | -71.7% | $305.9K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 87,800 | 62,400 | -28.9% | $293.3K | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 21,976 | 61,555 | +180.1% | $289.3K | 2026-Q1 |
| HB Wealth Management, LLC | DOUBLED | 25,000 | 50,000 | +100.0% | $235.0K | 2026-Q1 |
| Financial Engines Advisors L.L.C. | EXIT | 3,828,717 | 0 | -100.0% | $0.00 | 2026-Q1 |
| FMR LLC | ADD | 15,396,200 | 24,688,109 | +60.4% | $105.2M | 2025-Q4 |
| Point72 Asset Management, L.P. | ADD | 4,068,575 | 5,189,538 | +27.6% | $22.1M | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 644,982 | 5,140,931 | +697.1% | $21.9M | 2025-Q4 |
| Financial Engines Advisors L.L.C. | DOUBLED | 1,381,357 | 3,828,717 | +177.2% | $16.3M | 2025-Q4 |
5 unique insiders with 15 transactions. Net insider value: -$1.2M ($0.00 bought, $1.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | Ogden Christopher | Chief Financial Officer | SELL | 19,323 | $6.42 | $124.1K |
| Mar 17, 2026 | BELVIN MARCIA | SVP, Chief Scientific Officer | SELL | 31,492 | $6.42 | $202.3K |
| Mar 17, 2026 | McCarthy Sean A. | CEO | SELL | 118,969 | $6.42 | $764.1K |
| Mar 17, 2026 | Chu Yu-Waye | Chief Medical Officer | SELL | 21,279 | $6.42 | $136.7K |
| Feb 2, 2026 | Chu Yu-Waye | Chief Medical Officer | AWARD | 75,000 | — | — |
| Feb 2, 2026 | Chu Yu-Waye | Chief Medical Officer | AWARD | 300,000 | — | — |
| Feb 2, 2026 | Lester Rachael | Chief Business Officer | AWARD | 20,000 | — | — |
| Feb 2, 2026 | Lester Rachael | Chief Business Officer | AWARD | 50,000 | — | — |
| Feb 2, 2026 | Lester Rachael | Chief Business Officer | AWARD | 50,000 | — | — |
| Feb 2, 2026 | BELVIN MARCIA | SVP, Chief Scientific Officer | AWARD | 60,000 | — | — |
| Feb 2, 2026 | BELVIN MARCIA | SVP, Chief Scientific Officer | AWARD | 250,000 | — | — |
| Feb 2, 2026 | Ogden Christopher | Chief Financial Officer | AWARD | 90,000 | — | — |
| Feb 2, 2026 | Ogden Christopher | Chief Financial Officer | AWARD | 325,000 | — | — |
| Feb 2, 2026 | McCarthy Sean A. | CEO | AWARD | 210,000 | — | — |
| Feb 2, 2026 | McCarthy Sean A. | CEO | AWARD | 980,000 | — | — |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
NEUTRAL
6/10
CytomX Therapeutics priced a public offering of 45,990,567 shares and pre-funded warrants for 1,179,
Mar 18, 2026
BEARISH
7/10
CytomX Therapeutics announced a public offering of $250.0 million in common stock and pre-funded war
Mar 16, 2026
MIXED
6/10
CytomX Therapeutics reported financial results for 2025, highlighted by a significant revenue declin
Mar 16, 2026
NEUTRAL
3/10
CytomX Therapeutics announced it will report full year 2025 financial results on March 16, 2026, bef
Mar 4, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 15 analysts: 7 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$12.50 mean target
+315.3% upside
Strong Buy (1.38)
$6.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $3.01 |
| Target Low | $6.00 |
| Target Mean | $12.50 |
| Target Median | $12.00 |
| Target High | $16.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.38) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.10 | $-0.13 | $-0.07 | 0.0% | +1.2% | 2↑ 4↓ | $0.0B | -33.9% | 6 |
| Next Q 2026-09-30 |
$-0.11 | $-0.14 | $-0.07 | -16.9% | +4.5% | 3↑ 3↓ | $0.0B | 3.4% | 6 |
| Current FY 2026-12-31 |
$-0.42 | $-0.51 | $-0.34 | -180.6% | +2.9% | 2↑ 4↓ | $0.0B | -53.1% | 6 |
| Next FY 2027-12-31 |
$-0.49 | $-0.81 | $-0.25 | -15.4% | +2.1% | 3↑ 3↓ | $0.0B | -4.2% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.101 | |
| 7d ago | $-0.104 | +0.003 |
| 30d ago | $-0.102 | +0.001 |
| 60d ago | $-0.067 | -0.034 |
| 90d ago | $-0.056 | -0.045 |
8 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 19, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 18, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | JP Morgan | UPGRADE | Neutral | Overweight |
| Mar 9, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Feb 4, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Feb 4, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | Guggenheim | INITIATE | — | Buy |
| Jan 20, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Jan 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
CTMX is having their Q1 announcement on the 7th
▲ 1
💬 1
⚡ 0.5
Jun 3, 2026
contract
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
<p align="center"><em>- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s P
Jun 2, 2026
short_volume
Short Volume: CTMX — 57.8% short (1.2M / 2.1M)
Short: 1,214,084 | Exempt: 37 | TRF Vol: 2,099,354 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: CTMX — 55.9% short (0.6M / 1.1M)
Short: 628,037 | Exempt: 5,000 | TRF Vol: 1,123,846 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: CTMX — 67.2% short (1.7M / 2.5M)
Short: 1,652,139 | Exempt: 0 | TRF Vol: 2,459,891 | Short Ratio: 67.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
other
CytomX Therapeutics to Present at Upcoming June Investor Conferences
<p align="left">SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of mas
May 7, 2026
earnings
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
<p align="center"><em>- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients
May 4, 2026
short_volume
Short Volume: CTMX — 58.6% short (0.6M / 1.0M)
Short: 577,300 | Exempt: 0 | TRF Vol: 984,994 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings_calendar
CTMX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 29, 2026
short_volume
Short Volume: CTMX — 65.5% short (0.5M / 0.7M)
Short: 468,847 | Exempt: 0 | TRF Vol: 716,292 | Short Ratio: 65.5% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: CTMX — 75.8% short (1.0M / 1.4M)
Short: 1,039,514 | Exempt: 0 | TRF Vol: 1,370,596 | Short Ratio: 75.8% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: CTMX — 72.4% short (0.8M / 1.1M)
Short: 823,878 | Exempt: 0 | TRF Vol: 1,137,958 | Short Ratio: 72.4% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: CTMX — 56.9% short (0.5M / 0.8M)
Short: 476,404 | Exempt: 0 | TRF Vol: 837,948 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: CTMX — 61.4% short (0.9M / 1.5M)
Short: 942,713 | Exempt: 7,030 | TRF Vol: 1,534,782 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: CTMX — 58.6% short (2.1M / 3.6M)
Short: 2,135,832 | Exempt: 0 | TRF Vol: 3,646,273 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: CTMX — 61.3% short (1.9M / 3.2M)
Short: 1,932,659 | Exempt: 275 | TRF Vol: 3,150,714 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)